{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:42:48Z","timestamp":1777563768911,"version":"3.51.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Cancer Institute UNC Immunotherapy Training","award":["T32 1T32CA28527-01"],"award-info":[{"award-number":["T32 1T32CA28527-01"]}]},{"DOI":"10.13039\/100006292","name":"Infectious Disease Society of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006292","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Amy Strelzer Manasevit"},{"DOI":"10.13039\/100001738","name":"Be The Match Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["AI163365"],"award-info":[{"award-number":["AI163365"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012264","name":"NIH","doi-asserted-by":"publisher","award":["R01 155098"],"award-info":[{"award-number":["R01 155098"]}],"id":[{"id":"10.13039\/501100012264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013506","name":"UNC Center for Gastrointestinal Biology and Disease","doi-asserted-by":"publisher","award":["UL1TR002489"],"award-info":[{"award-number":["UL1TR002489"]}],"id":[{"id":"10.13039\/100013506","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007930","name":"Clinical and Translational Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Infections are increasingly recognized as a complication of chimeric antigen receptor T-cell (CAR-T) therapy however the incidence of infections after non-CD19 targeted CAR-T is not yet known. We report, for the first time, infectious complications after CD30 CAR T-cell treatment for patients with Hodgkin lymphoma and peripheral T-cell lymphoma.<\/jats:p>\n               <jats:p>We retrospectively evaluated all 64 adult patients with relapsed\/refractory CD30+ lymphomas who received anti-CD30 CAR T-cells at a single institution between 2016\u20132021. We assessed microbiologically confirmed infections within 1 year after cell infusion, censoring for relapse. We calculated infection density (total infections per 100 patient-days-at-risk), and cumulative incidence of infection divided into time periods postinfusion (days 0\u201328, 29\u201390, and 91\u2013365). We compared infectious outcomes to a concurrent cohort of CD19 CAR-T recipients (n = 50) at the same institution.<\/jats:p>\n               <jats:p>Infection density in the first year after CD30 CAR T-cell infusion was 0.131 per 100 patient-days-at-risk, with 17 patients developing 19 total infections including 15 mild, 3 moderate, and 1 severe infection (1-year cumulative incidence of 32%; 95% confidence interval [CI], 19\u201347]). Infections were primarily viral (30%; 95% CI, 17\u201344) and most common early after infusion. Far fewer infections were bacterial in CD30 CAR-T recipients (4.9%; 95% CI, 1.3\u201313), in contrast to the CD19 cohort in which bacterial infections predominated and were more severe.<\/jats:p>\n               <jats:p>Microbiologically confirmed infections, primarily with respiratory viruses, were most common in the first 28 days after CD30 CAR-T infusion and most were mild. Our findings may have implications for antimicrobial prophylaxis guidelines after CD30 CAR-T therapy.<\/jats:p>","DOI":"10.1093\/ofid\/ofaf541","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:40:11Z","timestamp":1758328811000},"source":"Crossref","is-referenced-by-count":2,"title":["Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5587-3994","authenticated-orcid":false,"given":"Felicia","family":"Cao","sequence":"first","affiliation":[{"name":"Divisions of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8981-4638","authenticated-orcid":false,"given":"Yueling","family":"Xiu","sequence":"additional","affiliation":[{"name":"Gillings School of Public Health, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2536-0200","authenticated-orcid":false,"given":"Michael","family":"Mohnasky","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4568-1092","authenticated-orcid":false,"given":"Jonathan S","family":"Serody","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3983-5534","authenticated-orcid":false,"given":"Paul","family":"Armistead","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpietro","family":"Dotti","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"Department of Microbiology and Immunology, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2702-0381","authenticated-orcid":false,"given":"Melody","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Blood & Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University , Stanford, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9529-036X","authenticated-orcid":false,"given":"Jonathan","family":"Huggins","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6411-198X","authenticated-orcid":false,"given":"Julia","family":"Messina","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhanu","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Saullo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University , Durham, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Stromberg","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish K","family":"Saha","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Walsh","sequence":"additional","affiliation":[{"name":"School of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Savoldo","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"Division of Hematology-Oncology, Department of Pediatrics, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1346-3157","authenticated-orcid":false,"given":"Natalie","family":"Grover","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather I","family":"Henderson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-7400","authenticated-orcid":false,"given":"Tessa M","family":"Andermann","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]},{"name":"Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"2025092508530966600_ofaf541-B1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10428199509059636","article-title":"CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy","volume":"18","author":"Scheuermann","year":"1995","journal-title":"Leuk Lymphoma"},{"key":"2025092508530966600_ofaf541-B2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"2025092508530966600_ofaf541-B3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster Stephen","year":"2019","journal-title":"N Engl J Med"},{"key":"2025092508530966600_ofaf541-B4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2025092508530966600_ofaf541-B5","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke Frederick","year":"2022","journal-title":"N Engl J Med"},{"key":"2025092508530966600_ofaf541-B6","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"key":"2025092508530966600_ofaf541-B7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The other side of CAR T-cell therapy: cytokine release syndrome, neurologic toxicity, and financial burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"16_suppl","key":"2025092508530966600_ofaf541-B8","doi-asserted-by":"crossref","first-page":"7528","DOI":"10.1200\/JCO.2023.41.16_suppl.7528","article-title":"Rates of cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T)","volume":"41","author":"Frigault","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025092508530966600_ofaf541-B9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"2025092508530966600_ofaf541-B10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"2025092508530966600_ofaf541-B11","doi-asserted-by":"crossref","first-page":"09636897211025503","DOI":"10.1177\/09636897211025503","article-title":"Incidence and risk factors associated with infection after chimeric antigen receptor T cell therapy for relapsed\/refractory B-cell malignancies","volume":"30","author":"Zhu","year":"2021","journal-title":"Cell Transplant"},{"key":"2025092508530966600_ofaf541-B12","doi-asserted-by":"crossref","first-page":"104134","DOI":"10.1016\/j.critrevonc.2023.104134","article-title":"Infections in haematology patients treated with CAR-T therapies: a systematic review and meta-analysis","volume":"192","author":"Reynolds","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025092508530966600_ofaf541-B13","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2025092508530966600_ofaf541-B14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.V66.4.848.848","article-title":"The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells","volume":"66","author":"Stein","year":"1985","journal-title":"Blood"},{"key":"2025092508530966600_ofaf541-B15","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.3324\/haematol.2013.084913","article-title":"CD30 expression in peripheral T-cell lymphomas","volume":"98","author":"Sabattini","year":"2013","journal-title":"Haematologica"},{"key":"2025092508530966600_ofaf541-B16","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"van der Weyden","year":"2017","journal-title":"Blood Cancer J"},{"key":"2025092508530966600_ofaf541-B17","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025092508530966600_ofaf541-B18","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00277-021-04689-4","article-title":"Quality of life of survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: a LYSA study","volume":"101","author":"Paunescu","year":"2022","journal-title":"Ann Hematol"},{"key":"2025092508530966600_ofaf541-B19","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.19.03160","article-title":"Health-related quality of life in patients with Hodgkin lymphoma: a longitudinal analysis of the German Hodgkin Study Group","volume":"38","author":"Kreissl","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025092508530966600_ofaf541-B20","doi-asserted-by":"crossref","first-page":"540.e1","DOI":"10.1016\/j.jtct.2024.03.001","article-title":"Defining and grading infections in clinical trials involving hematopoietic cell transplantation: a report from the BMT CTN Infectious Disease Technical Committee","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025092508530966600_ofaf541-B21","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QCO.0000000000000679","article-title":"Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties","volume":"33","author":"Haidar","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2025092508530966600_ofaf541-B22","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2025092508530966600_ofaf541-B23","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by The American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"2025092508530966600_ofaf541-B24","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2352-3026(24)00064-4","article-title":"Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30 + lymphoma: a phase 1 study","volume":"11","author":"Grover","year":"2024","journal-title":"Lancet Haematol"},{"key":"2025092508530966600_ofaf541-B25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025092508530966600_ofaf541-B26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/cid\/cir523","article-title":"Defining bloodstream infections related to central venous catheters in patients with cancer: a systematic review","volume":"53","author":"Tomlinson","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025092508530966600_ofaf541-B27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2025092508530966600_ofaf541-B28","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/9\/ofaf541\/64316902\/ofaf541.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/9\/ofaf541\/64316902\/ofaf541.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:53:18Z","timestamp":1758804798000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf541\/8257715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,8,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf541","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,29]]},"article-number":"ofaf541"}}